[
  {
    "question_type": "单选",
    "chapter_code": "C11",
    "chapter_title": "第十一章 肿瘤治疗与支持用药",
    "section_code": "C11.2",
    "section_title": "第二节 靶向与免疫",
    "knowledge_point_code": "C11.2.1",
    "knowledge_point_title": "EGFR 靶向治疗耐药",
    "stem": "肺腺癌患者使用吉非替尼 8 个月后出现突变 T790M，接下来应选哪种药物？",
    "options": {
      "A": "奥希替尼",
      "B": "培美曲塞",
      "C": "贝伐珠单抗",
      "D": "阿替利珠单抗",
      "E": "紫杉醇"
    },
    "answer": "A",
    "explanation": "T790M 突变是吉非替尼耐药的常见机制，应切换到可覆盖该突变的三代 EGFR 抑制剂奥希替尼。"
  }
]

